The Rogan-architect FDA appointee will not shorten the Lykos/MDMA review timeline; any decision follows standard PDUFA cadence with no expedited action announced this quarter.

The FDA (the US drug regulator) rejected a company called Lykos Therapeutics' application to approve MDMA-assisted therapy in 2024 and asked for more data. A new FDA official with ties to podcaster Joe Rogan has been appointed, raising hopes among some that the review might speed up. This prediction says that won't happen — the review will follow its normal, legally scheduled timeline, and no fast-tracked decision will be announced in the next few months.

Political appointment optics don't override division-level review rigor. Fast-tracking on ideology invites litigation and erodes the standard patients depend on.